摘要
目的评价沙库巴曲缬沙坦钠片(商品名:诺欣妥)联合人重组脑钠肽治疗左室射血分数(LVEF)≤35%顽固性心力衰竭(心衰)的效果。方法70例LVEF≤35%顽固性心衰患者,随机分为观察组及对照组,每组35例。对照组按照常规慢性心衰方法治疗,观察组除血管紧张素转化酶抑制剂(ACEI)/血管紧张素受体拮抗剂(ARB)以外的治疗与对照组相同,同时再加用诺欣妥联合人重组脑钠肽治疗。比较两组治疗效果、不良反应发生情况及治疗前后左室舒张末期内径(VEDD)、LVEF、脑钠肽(BNP)水平。结果观察组总有效率为91.43%,高于对照组的68.57%,差异有统计学意义(P<0.05)。治疗后,两组BNP水平均较本组治疗前降低,且观察组BNP水平(423.1±78.7)ng/L低于对照组的(984.6±94.8)ng/L,差异有统计学意义(P<0.05)。治疗后,两组LVEF和LVEDD均较治疗前改善,且观察组LVEF(57.2±8.2)%高于对照组的(39.6±9.4)%,LVEDD(52.1±5.5)mm小于对照组的(64.5±5.3)mm,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论诺欣妥联合人重组脑钠肽在治疗顽固性心衰方面有显著疗效,且安全性较好,值得推广。
Objective To evaluate the effect of sacubitril valsartan sodium tablets(trade name:Novartis)combined with recombinant human brain natriuretic peptide in the treatment of refractory heart failure with left ventricular ejection fraction(LVEF)≤35%.Methods A total of 70 cases of refractory heart failure with LVEF≤35% were randomly divided into observation group and control group,with 35 cases in each group.The control group was treated according to the conventional chronic heart failure method,while the observation group was treated with the same treatment as the control group except for angiotensin-converting enzyme inhibitor(ACEI)/angiotensin receptor blockers(ARB),with the addition of Novartis combined with recombinant human brain natriuretic peptide.The therapeutic effects,occurrence of adverse reactions and the levels of left ventricular end diastolic diameter(LVEDD),LVEF and brain natriuretic peptide(BNP)before and after treatment were compared between the two groups.Results The total effective rate of the observation group was 91.43%,which was higher than 68.57% of the control group,and the difference was statistically significant(P<0.05).After treatment,the BNP level of the two groups was lower than that of this group before treatment,and the BNP level(423.1±78.7)ng/L of the observation group was lower than(984.6±94.8)ng/L of the control group.All the differences were statistically significant(P<0.05).After treatment,the LVEF and LVEDD of the two groups were improved compared with those of this group before treatment,and the LVEF(57.2±8.2)% of the observation group was higher than(39.6±9.4)% of the control group,and the LVEDD(52.1±5.5)mm was less than(64.5±5.3)mm of the control group.All the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Novartis combined with recombinant human brain natriuretic peptide has significant effect and high safety in the treatment of refrac
作者
孙奇
孙菲
韩玉泽
SUN Qi;SUN Fei;HAN Yu-ze(Emergency Department,Dalian Geriatric Hospital,Dalian 116000,China)
出处
《中国现代药物应用》
2022年第2期8-11,共4页
Chinese Journal of Modern Drug Application
关键词
沙库巴曲缬沙坦钠片
人重组脑钠肽
左室射血分数≤35%
顽固性心力衰竭
Sacubitril valsartan sodium tablets
Recombinant human brain natriuretic peptide
Left ventricular ejection fraction≤35%
Refractory heart failure
